Aneurysmal Subarachnoid Hemorrhage - Pipeline Insight, 2024

This “Aneurysmal Subarachnoid Hemorrhage- Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Aneurysmal Subarachnoid Hemorrhage pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Aneurysmal Subarachnoid Hemorrhage: Understanding

Aneurysmal Subarachnoid Hemorrhage: Overview

Aneurysmal subarachnoid hemorrhage (SAH) is a worldwide health burden with high fatality and permanent disability rates. The overall prognosis depends on the volume of the initial bleed, rebleeding, and the degree of delayed cerebral ischemia (DCI). The subarachnoid space is the area between the brain and the skull. It is filled with cerebrospinal fluid (CSF), which acts as a floating cushion to protect the brain. When blood is released into the subarachnoid space, it irritates the lining of the brain, increases pressure on the brain, and damages brain cells. At the same time, the area of brain that previously received oxygen-rich blood from the affected artery is now deprived of blood, resulting in a stroke. Aneurysmal Subarachnoid Hemorrhage is frequently a sign of a ruptured aneurysm.

A defining characteristic of SAH is the development of spasm in large cerebral vessels. Vasospasm has been documented at both the early and chronic stages of the injury. A leading hypothesis in DCI assumes that cerebral vasospasm causes global ischemic tone in the SAH brain. This, in turn, leads to neuronal dysfunction and, ultimately, cognitive deficits. As such, preclinical and clinical trials of vasodilators were undertaken. Unfortunately, most of these studies clearly show that the resolution of cerebral vasospasm does not attenuate the development of DND after SAH. For example, the administration of the endothelin-1a antagonist clazosentan ameliorates vascular spasm without improving outcomes. On the other hand, administration of nimodipine, a calcium-channel blocker, attenuates the neurological outcome with no change in vascular spasm. These results demonstrate that, though important, cerebral vasospasm is, at best, not the only cause of DND. Re-evaluation of older data and new studies have led to a new hypothesis that immune system activation (i.e., inflammation) in the CNS is critical to the development of DND. The common symptoms include: sudden onset of a severe headache (often described as the worst headache of my life), nausea and vomiting, stiff neck, sensitivity to light (photophobia), blurred or double vision, loss of consciousness, and seizures. SAH caused by injury is often seen in older people who have fallen and hit their heads. Among the young, the most common injury leading to SAH is motor vehicle accidents. Five to 10% of strokes are caused by SAH.

Cytokine analysis has shed some light on the possible mechanisms involved in DND (there are currently excellent reviews detailing the inflammatory cytokine profiles in the brain and periphery after SAH and their contribution to vascular dysregulation). Indeed, many clinical trials targeting inflammatory molecules have been undertaken. However, the ultimate effectors of damage are inflammatory cells.

An aneurysmal cause of SAH has similar risk factors associated with aneurysm formation. Hypertension, cigarette smoking, and family history are the most consistently observed risk factors. Other factors include alcohol, sympathomimetic drugs, and estrogen deficiency. The treatment for subarachnoid hemorrhage varies, depending on the underlying cause of the bleeding and the extent of damage to the brain. Treatment may include lifesaving measures, symptom relief, repair of the bleeding vessel, and complication prevention.

Aneurysmal Subarachnoid Hemorrhage- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Aneurysmal Subarachnoid Hemorrhage pipeline landscape is provided which includes the disease overview and Aneurysmal Subarachnoid Hemorrhage treatment guidelines. The assessment part of the report embraces, in depth Aneurysmal Subarachnoid Hemorrhage commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Aneurysmal Subarachnoid Hemorrhage collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Aneurysmal Subarachnoid Hemorrhage R&D. The therapies under development are focused on novel approaches to treat/improve Aneurysmal Subarachnoid Hemorrhage.

Aneurysmal Subarachnoid Hemorrhage Emerging Drugs Chapters

This segment of the Aneurysmal Subarachnoid Hemorrhage report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Aneurysmal Subarachnoid Hemorrhage Emerging Drugs

GTX-104: Acasti PharmaNovel aqueous nanoparticle formulation of water-insoluble nimodipine (GTX-104) that enables a continuous peripheral IV infusion for rapid and enhanced bioavailability. Acasti believes GTX-104 can potentially improve the management of hypotension and vasospasm in SAH patients, thereby improving patient outcomes and potentially preventing death and/or reducing long-term disability. Acasti Pharma announced the anticipation of guidance on its proposed Phase III by the US FDA for subarachnoid hemorrhage in the first quarter of 2023. A Type C meeting is planned in the first quarter of 2023 with the US FDA to confirm the proposed Phase III safety trial for GTX 104 and discuss the requirements to submit an NDA under Section 505(b) (937797). Currently, the drug is being evaluated in the Phase III clinical trial for the treatment of patients with aneurysmal subarachnoid haemorrhage.

Nicardipine: BIT PharmaA potent calcium channel blocker with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. Nicardipine is currently being evaluated in the Phase II clinical trial for the treatment of patients with aneurysmal subarachnoid haemorrhage.

Aneurysmal Subarachnoid Hemorrhage: Therapeutic Assessment

This segment of the report provides insights about the different Aneurysmal Subarachnoid Hemorrhage drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Aneurysmal Subarachnoid Hemorrhage

• There are approx. 8+ key companies which are developing the therapies for Aneurysmal Subarachnoid Hemorrhage. The companies which have their Aneurysmal Subarachnoid Hemorrhage drug candidates in the most advanced stage, i.e. phase II include, BIT Pharma.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Aneurysmal Subarachnoid Hemorrhage pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Aneurysmal Subarachnoid Hemorrhage: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Aneurysmal Subarachnoid Hemorrhage therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Aneurysmal Subarachnoid Hemorrhage drugs.

Aneurysmal Subarachnoid Hemorrhage Report Insights

• Aneurysmal Subarachnoid Hemorrhage Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Aneurysmal Subarachnoid Hemorrhage Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Aneurysmal Subarachnoid Hemorrhage drugs?
• How many Aneurysmal Subarachnoid Hemorrhage drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Aneurysmal Subarachnoid Hemorrhage?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Aneurysmal Subarachnoid Hemorrhage therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Aneurysmal Subarachnoid Hemorrhage and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• BIT Pharma
• Acasti Pharma
• Cenyx Biotech
• Avilex Pharma

Key Products

• Nicardipine
• GTX-104
• AVLX-144
• CX213

This product will be delivered within 1-3 business days.